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Background: Neuroprotective and neurotrophic properties of leukemia inhibitory factor (LIF) have been widely
reported. In the central nervous system (CNS), astrocytes are the major source for LIF, expression of which is
enhanced following disturbances leading to neuronal damage. How astrocytic LIF expression is regulated, however,
has remained an unanswered question. Since neuronal stress is associated with production of extracellular
adenosine, we investigated whether LIF expression in astrocytes was mediated through adenosine receptor
signaling.
Methods: Mouse cortical neuronal and astrocyte cultures from wild-type and adenosine A2B receptor knock-out
animals, as well as adenosine receptor agonists/antagonists and various enzymatic inhibitors, were used to study
LIF expression and release in astrocytes. When needed, a one-way analysis of variance (ANOVA) followed by
Bonferroni post-hoc test was used for statistical analysis.
Results: We show here that glutamate-stressed cortical neurons induce LIF expression through activation of
adenosine A2B receptor subtype in cultured astrocytes and require signaling of protein kinase C (PKC),
mitogen-activated protein kinases (MAPKs: p38 and ERK1/2), and the nuclear transcription factor (NF)-κB. Moreover,
LIF concentration in the supernatant in response to 5′-N-ethylcarboxamide (NECA) stimulation was directly
correlated to de novo protein synthesis, suggesting that LIF release did not occur through a regulated release
pathway. Immunocytochemistry experiments show that LIF-containing vesicles co-localize with clathrin and Rab11,
but not with pHogrin, Chromogranin (Cg)A and CgB, suggesting that LIF might be secreted through recycling
endosomes. We further show that pre-treatment with supernatants from NECA-treated astrocytes increased survival
of cultured cortical neurons against glutamate, which was absent when the supernatants were pre-treated with an
anti-LIF neutralizing antibody.
Conclusions: Adenosine from glutamate-stressed neurons induces rapid LIF release in astrocytes. This rapid release
of LIF promotes the survival of cortical neurons against excitotoxicity.
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Leukemia inhibitory factor (LIF) is a soluble glycopro-
tein that belongs to the family of interleukin (IL)-6-type
cytokines. Other members of this family include IL-6,
IL-11, ciliary neurotrophic factor (CNTF), oncostatin M
(OSM), cardiotrophin-1 (CT-1) and novel neurotrophin-
1 (NNT-1) [1], which display pronounced trophic as
well as protective properties during pathophysiology of
the central nervous system (CNS) and are hence re-
ferred to as neuropoietic cytokines or neurokines [2].
Specific functions of LIF in the nervous system include
induction of cholinergic differentiation of sympathetic
neurons, induction of neuropeptide and choline acetyl-
transferase (ChAT) gene expression [3], regulation of
polyneuronal innervation of neuromuscular junction
[4,5] and regulation of the HPA axis [6,7]. Furthermore,
LIF signaling is crucial for development of the nervous
system, including development of sensory and motor
neurons [8,9] and glial cells [10]. Consistently, reduced
numbers of astrocytes and oligodendrocytes are found
in LIF knock-out mice [11]. During inflammation, LIF
has been suggested to be both pro- and anti-
inflammatory and appears to play a key role in neural
injury and regeneration. We and others have previously
demonstrated the neuroprotective properties of LIF
against damages caused by excitotoxicity, light, et cetera
[12-14]. Moreover, promotion of axonal regeneration
and oligodendrocyte growth and survival by LIF suggests
its potential for reducing damage associated with central
inflammatory demyelinating diseases such as multiple
sclerosis [15-17].
In the CNS, astrocytes are considered to be the major
source for LIF [18,19], and its expression in the brain is
significant during pathological conditions including is-
chemia [20,21], multiple sclerosis [22], Alzheimer’s and
Parkinson’s diseases [23] and brain injury [24]. The fac-
tors responsible for elevated LIF induction during CNS
pathology are largely unknown. One of the candidates
identified recently to induce LIF expression in astrocytes
is ATP [18,25], levels of which also rise during condi-
tions like high-frequency neuronal activity, seizure, is-
chemia and hypoxia [26,27]. However, extracellular ATP
is rapidly hydrolyzed by a cascade of ectonucleotidases
resulting in an enhanced level of adenosine [26,28]. Cor-
respondingly, excitotoxic conditions such as ischemia,
hypoxia, seizure and head injury are known to induce a
rapid increase in extracellular adenosine concentrations,
up to 100 times that of the resting concentration [29-
33]. There is abundant evidence for immune regulation
by adenosine [34] including expression and release of
growth factors and cytokines such as nerve growth factor
(NGF), S100beta, IL-6 and CCL2 in glial cells [35-39].
However, it is not known whether adenosine can induce
LIF expression in astrocytes.In the present study, we investigated the potential in-
fluence of adenosine receptor activity on LIF release
from cultured astrocytes.
Methods
Chemicals and reagents
Neurobasal media, Hank’s balanced salt solution (HBSS),
phosphate-buffered saline (PBS), sodium pyruvate, L-
glutamine, penicillin-streptomycin, hydroxyethyl pipera-
zineethanesulfonic acid (HEPES), glutaMAX-1 and B27
supplement were obtained from Gibco (Breda, The
Netherlands). Dulbecco’s modified Eagle’s medium
(DMEM) and fetal calf serum (FCS) were obtained from
PAA Laboratories (Cölbe, Germany). Trypsin was ob-
tained from Life Technologies (Breda, The Netherlands).
L-leucine methyl ester (LME) and the remaining cell
medium components were purchased from Sigma-
Aldrich (Zwijndrecht, The Netherlands). Recombinant
mouse LIF (rmLIF: LIF2005) was obtained from Milli-
pore (Amsterdam, The Netherlands). Brefeldin A (BFA),
caffeine, L-glutamate, adenosine A2B receptor antagonist
(MRS 1754), protein kinase A (PKA) inhibitor (KT
5720), protein kinase C (PKC) inhibitor (Ro 31–8220),
p38 mitogen-activated protein kinases (MAPK) inhibitor
(SB 203580), and adenosine analog (5′-N-Ethylcarboxa-
mide or NECA) were obtained from Sigma-Aldrich
(Zwijndrecht, The Netherlands). Non-hydrolysable ATP
(2MeSATP), adenosine A2A receptor antagonist (ZM
241385), adenosine A2A receptor agonist (CGS 21680)
and MEK1/2 inhibitor (U 0126) were obtained from
Tocris Bioscience (Bristol, UK). NF-kB inhibitor (BAY
11–7082) and c-Jun N-terminal kinase (JNK) inhibitor (SP
600125) were obtained from Calbiochem (Darmstadt,
Germany). Reagents used in immunoblotting experiments
were purchased from Bio-Rad Laboratories (Veenendaal,
The Netherlands) with the exception of the polyvinylidene
fluoride (PVDF) membranes that were obtained from
Millipore (Bedford, MA).
Animals
Wild-type C57BL/6 J (1 to 2 days postnatal) mice were
obtained from Central Laboratory Animal Facility (Uni-
versity of Groningen, The Netherlands). Adenosine A2B
receptor knock-out (A2B KO) mice (1 to 2 days postna-
tal) with the same genetic background were kindly pro-
vided by Professor Marco Idzko (University of Freiburg,
Germany). Wild-type C57BL/6 J (14 to 15 days em-
bryonic) mice were obtained from Harlan (Horst, The
Netherlands). All procedures were in accordance with
the regulation of the Ethical Committee for the use of
experimental animals of the University of Groningen,
The Netherlands (License number DEC 4623A and DEC
5913A). Animals were housed in standard MakrolonTM
(Bayer AG, Leverkusen, Germany) cages and maintained
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water ad libitum.
Primary neuronal culture
Primary culture of cortical neurons from mouse embryo
(~E15) was established as described previously [13].
Briefly, cortices from embryonic brains were dissected in
ice-cold HBSS supplemented with 30% glucose. Menin-
ges were removed, and the tissues were treated with
trypsin before they were gently dissociated by trituration
in neuronal culture media (neurobasal medium supple-
mented with 2% B27, 1 mM sodium pyruvate, 2 mM L-
glutamine and 50 U/mL penicillin-streptomycin). The
cell suspension was filtered using cell strainer (70 μm)
(BD Falcon, Franklin Lakes, NJ, USA) before centrifuga-
tion (800 rpm for 10 minutes). Cells were then seeded
on poly-D-lysine-coated six-well plates (1.5 x 106 cells/
well) and maintained in neuronal culture media in a hu-
midified atmosphere with 5% CO2 at 37°C. The culture
medium was refreshed the next day to get rid of debris.
The neuronal purity as determined by Microtubule-
associated protein 2 (MAP2)-staining was around 98%
(data not shown) [13]. Cultures were used after 5 days
in vitro.
Induction of excitotoxicity
Cortical neuron cultures were subjected to an excito-
toxic challenge with glutamate (50 μM, for 1 hour), after
which cultures were refreshed with fresh media and
were incubated at 37°C. Supernatants from neuron cul-
tures (untreated and glutamate-treated) were collected
18 hours after glutamate challenge and were applied to
the primary astrocyte cultures.
Primary astrocyte cultures
Primary astrocyte cultures were established from cere-
bral cortices of postnatal (1 to 2 days) C57BL/6 J and
A2B KO mice according to a previously described pro-
cedure [40], which was modified to reduce microglial
contamination [41]. Microglial cells were separated from
the astrocytic monolayer by 1-hour shake-off at
150 rpm. This procedure was repeated two times with
an interval of 4 days in vitro between each shake off, fol-
lowed by an overnight shake-off at 240 rpm to remove
oligodendrocyte precursor cells. Purified astrocytes were
washed with HBSS buffer containing 1 mM ethylenedia-
minetetraacetic acid (EDTA) and further detached using
HBSS with 0.1% trypsin. Cells were reseeded with fresh
astrocyte culture medium (DMEM supplemented with
5% FCS, 2 mM L-glutamine, 1 mM sodium pyruvate and
50 U/mL penicillin-streptomycin) in multi-well plates
(5 x 104 cells/cm2) and maintained in culture to con-
fluency. To further reduce microglial contamination,
confluent astrocyte cultures were treated with 5 mMLME, a lysosomotropic agent [42], for 4 to 5 hours.
Astrocytes were ready for experiments after 1 to 2 days.
Our cell preparations had a high percentage of astro-
cytes (≥95%), which was confirmed by immunostaining
against GFAP (astrocyte specific marker) and CD11b
(microglial specific marker) (data not shown).
Real-time polymerase chain reaction
Total RNA of primary astrocytes was extracted, puri-
fied and transcribed into cDNA as described previ-
ously [13]. Quality of the cDNA was examined using
the following housekeeping gene Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) primer pairs: Fw
5′-CATCCTGCACCACCAACTGCTTAG-3′ and Rev 5′-
GCCTGCTTCACCACCTTCTTGATG-3′[Accessionnum-
ber: NM-008084]. The effect of neuronal supernatants
and NECA on LIF mRNA expression in cultured astro-
cytes was analyzed by real-time PCR (qPCR) using the
iCycler and iQ™ SYBR™ Green supermix (Bio-Rad, Vee-
nendaal, The Netherlands ). Mouse Hypoxanthine phos-
phoribosyltransferase 1 (HPRT1) and GAPDH primers
were used for normalization to housekeeping genes
(data normalized to HPRT1 are not shown), and these
genes showed no variations in response to the experimen-
tal treatments. The primer pairs used for qPCR were: LIF
(Fw 5′-ATGTGCGCCTAACATGACAG-3′ and Rev 5′-
TATGCGACCATCCGATACAG-3′) [Accession number:
NM-008501]; GAPDH (Fw 5′-ATGGCCTTCCGTGTT
CCTAC-3′ and Rev 5′-GCCTGCTTCACCACCTTCTT-
3′) [Accession number: AF106860] and HPRT1 (Fw 5′-
GACTTGCTCGAGATGTCA-3′ and Rev 5′-TGTAATC
CAGCAGGTCAG-3′) [Accession number: NM-013556].
The comparative Ct method (amount of target amplicon
X in Sample S, normalized to a reference R and related
to a control sample C), was calculated by:
2 CtX; S CtR; Sð Þ  CtX;C CtR;Cð Þð Þ
and was used to determine the relative gene expression
levels [43].
Western blot
Western blotting on cultured cortical astrocytes was per-
formed as previously described [13]. Equal amounts of
protein (30 μg) were loaded to 12.5 or 15% sodium
dodecyl sulfate-polyacrylamide gels and subsequently
transferred to PVDF membranes. The membranes were
blocked using Odyssey™ Blocking Buffer (OBB; LI-COR
Biosciences, Cambridge, UK; diluted 1:1 in PBS) for
1 hour and incubated overnight at 4°C with different
combinations of primary antibodies (diluted in 1:1 OBB
and PBS + 0.1% Tween 20 (PBS-T)): mouse monoclonal
anti-β-actin (1:8000, Abcam, Cambridge, UK); rabbit
monoclonal anti-phospho-NF-κB p65 (Ser536) (1:1000,
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and rat monoclonal anti-LIF (MAB449; 1 μg/mL, R&D
Systems, Oxford, UK). The next day, membranes
were washed in PBS-T (four times for 5 minutes
each time) and incubated for 1 hour at room
temperature with appropriate fluorescence conjugated
secondary antibodies (diluted in PBS-T): donkey anti-
mouse IR Dye 680 (1:10000, LI-COR Biosciences,
Cambridge, UK); goat anti-rat IR Dye 680 (1:10000,
LI-COR); and donkey anti-rabbit IR Dye 800CW
(1:10000, LI-COR). Membranes were washed again in
PBS-T (four times for 5 minutes each time) and the
fluorescent bands were detected using LI-COR’s
Odyssey™ infrared imaging system.
Leukemia inhibitory factor ELISA
A total of 1 mL of supernatant was collected from each
well of the six-well plates of primary mouse astrocyte cul-
tures, and these samples were stored at −20°C. ELISA
plates (96-well, Costar, Corning Life Sciences, Amsterdam,
The Netherlands) were coated overnight at room
temperature with 100 μl/well of primary antibody goat
anti-LIF (AF449; 0.5 μg/mL, R&D Systems, Oxford, UK)
diluted in 0.01 M PBS (pH 7.4). The following day, the
plates were washed six times with wash buffer (0.25 M
Tris–HCl pH 8, 0.15 M NaCl, 0.05% Tween-20) using an
automated microplate washer and air dried (this step is
repeated after each incubation step). Plates were subse-
quently incubated for 1 hour at room temperature with
200 μl/well of blocking buffer (0.01 M PBS, 2% BSA).
After blocking, the plates were incubated with superna-
tants from astrocyte cultures (100 μl/well) for 2 hours at
room temperature. Two dilutions (1:2 and 1:4) of each
sample, diluted in incubation buffer (0.01 M PBS, 0.2%
gelatin, 0.05% Tween-20), were made in triplicates. The
plates were then incubated for 1 hour at room
temperature with 100 μl/well of the detection antibody,
biotinylated goat anti-LIF (BAF449; 0.05 μg/mL; R&D Sys-
tems, Oxford, UK) diluted in incubation buffer, followed
by an incubation for 30 minutes at room temperature with
100 μl/well of Streptavidin-horseradish peroxidase (HRP)
conjugate (1:8000, Sanquin Reagents, Amsterdam, The
Netherlands). The plates were then incubated for 15
to 20 minutes at room temperature with 100 μl/well
of TMB detection buffer (0.1 M acetate buffer, 0.1 M
sodium-acetate, pH adjusted with 1 M citric acid
(0.21 g/mL; dissolve 2 tablets of 3, 3′, 5, 5′-
tetramethyl benzidinedihydrochloride in 11 mL of
TMB buffer and add 2 μl of 30% H2O2)). Upon stable
color formation the reactions were stopped by adding
100 μl/well of 1 M H2SO4. Absorbance of the samples
was measured using VersaMax, a spectrophotometric
ELISA plate reader, and SoftMax Pro software (Molecu-
lar Devices, CA, USA) at 450 nm, with a backgroundcorrection at 575 nm. Recombinant mouse LIF (15 to
2000 pg/mL) was used to plot the standard curve.
MTT assay
Survival of cultured embryonic cortical neurons or
cultured neonatal astrocytes against various experi-
mental treatments was measured by the colorimetric
MTT (3-(4,5-dimethylthiazol-2-yl-) 2,5-diphenyltetra-
zolium bromide) assay, as described previously [44].
MTT solution (0.5 mg/mL final concentration) was
added to cultured cells and incubated for 4 hours,
after which, cells were lysed and MTT-formazan solu-
bilized in dimethyl sulfoxide (DMSO) on an orbital
shaker for 15 minutes. Optical density measure of each
sample was determined using an automated ELISA
reader - the Varioskan Flash spectral scanning multimode
reader (Thermo Scientific, FL, USA) at 570 nm, with a
background correction at 630 nm.
Immunocytochemistry and confocal microscopy
Astrocytes cultured on glass cover slips were fixed for
15 minutes in 4% paraformaldehyde. After several
washes in PBS, the cells were blocked for 45 minutes
with 5% normal goat serum (Vector Laboratories,
Burlingame, CA, USA) in PBS containing 0.1% TritonX
(Sigma, Zwijndrecht, The Netherlands). The cover slips
were then incubated overnight at 4°C with rat anti-LIF
primary antibody (5 μg/mL, R&D Systems, Oxford, UK)
in combination with one of the following primary anti-
bodies: rabbit anti-Rab11 (1:400, Zymed, San Francisco,
CA, USA); rabbit anti-chromogranin A&B (1:100,
Novus Biologicals, Cambridge, UK); mouse anti-clathrin
(1:1000, Abcam, Cambridge, UK); rabbit anti-pHogrin
C-terminal (1:100, kind gift of Professor J.C. Hutton
(Denver, USA)) and rabbit anti-giantin (1:1000, Covance,
Princeton, NJ, USA). The following day, cells were
rinsed three times with PBS and incubated for 1 hour
with the appropriate secondary antibodies: donkey anti-
rat CY3 (1:500, Jackson ImmunoResearch Laboratories,
Uden, The Netherlands); donkey anti-rabbit Alexa Fluor
488 (1:500, Molecular Probes, Leiden, The Netherlands)
and donkey anti-mouse Alexa Fluor 488 (1:500, Molecu-
lar Probes). The cover slips were then rinsed with PBS
and mounted on microscopic slide with Mowiol
(Sigma, Zwijndrecht, The Netherlands) and analyzed
with a Leica SP2 AOBS system (Leica Microsystems,
Rijswijk, The Netherlands). Pictures were deconvoluted
using the software Huygens Pro (SVI, Hilversum, The
Netherlands). Primary antibody omission served as the
control.
Statistical data analysis
The absolute data values were normalized to the control in
order to allow multiple comparisons. Statistical analyses
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followed by Bonferroni post-hoc test, using the Statistical
Package for the Social Sciences (SPSS, Chicago, IL, USA).
In all cases, P values < 0.05 were considered statistically
significant.
Results
Glutamate-challenged cortical neurons induce LIF
expression in cultured astrocytes through adenosine
receptor activation
We have previously shown that treatment of cultured
cortical neurons with glutamate (50 μM, for 1 hour)
reduces cell survival by 60%, when compared to un-
treated controls [13]. In order to investigate whether
neuronal death induces LIF synthesis in astrocytes,
supernatants from cultured cortical neurons were col-
lected 18 hours after glutamate treatment (50 μM for
1 hour) and applied to cultured cortical astrocytes. It is
shown here that treatment of cultured astrocytes for
2 hours with supernatant from untreated neurons did
not change LIF expression (Figure 1). On the other
hand, supernatant from glutamate-challenged neurons
induced approximately three times greater expression of
astrocytic LIF mRNA (Figure 1). The induction of LIF
mRNA expression by glutamate-challenged neuronal0.0
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Figure 1 Glutamate-stressed cortical neurons induce leukemia
inhibitory factor (LIF) gene expression in primary cortical
astrocytes, by a mechanism dependent on astrocytic adenosine
receptor activation. Supernatants of primary mouse cortical
neurons (NS) collected 18 hours following treatment without (untr.)
or with glutamate (glut.; 50 μM, for 1 hour) were applied (1:1
dilution by volume) to the primary cultured cortical astrocytes for
2 hours. Where indicated, astrocytes were pre-treated with caffeine
(50 μM) or a cocktail of adenosine A2A and A2B receptor antagonists
(A2A antagonist: ZM 241385, 250 nM; A2B antagonist: MRS 1754, 250
nM), for 30 minutes before incubation with neuronal supernatants
and were analyzed for LIF mRNA expression (relative to GAPDH)
using real-time PCR. Data are normalized to the control and
presented as Mean± SEM of three independent experiments.
P< 0.05.supernatants was absent in the presence of the non-
specific adenosine receptor antagonist (caffeine, 50 μM)
(Figure 1) and by cocktail of the specific adenosine A2
receptors antagonists (A2A antagonist: ZM 241385, 250
nM; A2B antagonist: MRS 1754, 250 nM) (Figure 1), sug-
gesting that enhanced LIF expression in astrocytes
induced by glutamate-challenged neuronal supernatants
is mediated through adenosine A2A and/or A2B receptor
subtypes.NECA-induced LIF expression and secretion levels in
cultured mouse astrocytes is concentration- and
time-dependent
In order to further investigate adenosine receptor-
mediated LIF expression in astrocytes, we used NECA, a
non-selective adenosine receptor agonist. As shown in
Figure 2A, NECA-induced LIF mRNA expression in cul-
tured astrocytes was concentration- and time-dependent,
with maximum induction after 2 hours of incubation
with 1 and 10 μM NECA. Subsequently, the effect of
NECA (1 μM) on LIF protein expression was analyzed
by Western blot. Elevated LIF protein expression was
detected after 1 hour of NECA treatment, with a max-
imum induction after 2 to 4 hours (Figure 2B). Consist-
ently, ELISA analysis revealed LIF protein content in
supernatants from untreated astrocyte cultures, which
increased in time upon treatment with NECA (1 μM)
(Figure 2C).NECA-induced LIF expression and secretion levels is
dependent on adenosine A2B receptor activation
In subsequent experiments, specific antagonists of ad-
enosine A2A and A2B receptors (ZM 241385 and MRS
1754, respectively) were used to identify the receptor
subtype involved in NECA-induced LIF expression and
release in cultured astrocytes. Pre-treatment of astro-
cytes with ZM 241385 (250 nM, added 30 minutes be-
fore NECA) did not abolish NECA-induced LIF mRNA
and protein expression (Figure 3A and 3C). In contrast,
NECA-induced LIF mRNA (Figure 3A) and protein ex-
pression (Figure 3C) and release (Figure 3D) were com-
pletely inhibited by MRS 1754 pre-incubation (250 nM,
added 30 minutes before NECA). In addition, specific
adenosine A2A receptor agonist (CGS 21680; 1 μM)
failed to induce LIF mRNA or protein expression and
release (Figure 3A, C, D). The involvement of A2B recep-
tors was further confirmed in A2B KO astrocytes where
NECA stimulation for up to 24 hours did not induce
LIF mRNA expression (Figure 3B). Instead, astrocytes
without A2B receptors responded to NECA stimulation
with a down-regulation of LIF mRNA at 8 and 24 hours
(Figure 3B). Taken together, these results clearly show
that NECA-induced LIF expression and release from
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Figure 2 NECA increases leukemia inhibitory factor (LIF) expression and secretion levels in primary mouse astrocytes. (A) Primary
cortical astrocytes were treated without or with NECA (1, 10 or 20 μM) for 0.5, 1, 2, 4, 8, 12 and 24 hours. Cells were then analyzed for LIF mRNA
expression (relative to GAPDH) by real-time PCR. Data are normalized to the control and presented as Mean± SEM of three independent
experiments. P< 0.05. (B) shows Western blot analysis of cultured astrocytes treated without or with NECA (1 μM) for 1, 2, 4, 6, 8 and 12 hours to
determine LIF protein levels. β-actin served as a loading control. (C) shows a representation of sandwich ELISA experiment performed to detect
LIF content in supernatants of cultured astrocytes that were treated without or with NECA (1 μM) for 1, 2, 4, 6, 8 and 12 hours. Each bar
corresponds to the mean concentration of LIF in triplicate samples; error bars indicate SEM. Observations were confirmed by repeating the
experiments two additional times. P< 0.05. NECA, 5′-N-ethylcarboxamide.
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of adenosine A2B receptors.
NECA-induced LIF expression and secretion levels in
primary astrocytes are mediated through the Gq/11-PLC-
PKC and MAPKs, but not through Gs-cAMP-PKA
pathway.
In order to analyze the intracellular signaling pathways
that couple A2B receptor activity and LIF expression and
release in astrocytes, various specific blockers of signal-
ing routes were used. To determine the potential toxicityof these blockers, cultured astrocytes were incubated for
24 hours with the used and the doubled concentration
of these blockers, and cellular survival was assessed by
MTT assay. None of the used blockers at the appropriate
concentration caused significant toxicity; the only
blocker that negatively influenced astrocytic survival at
the double concentration was the NF-κB inhibitor
BAY 11-7082 (Figure 4).
Adenosine A2B receptors are coupled to two types of
G-proteins: Gs and Gq/11 [45]. Activation of Gs proteins
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Figure 3 (See legend on next page.)
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Figure 3 NECA-induced leukemia inhibitory factor (LIF) expression and secretion levels in primary astrocytes are dependent on
adenosine A2B receptor activation. Primary cortical astrocytes were treated with the adenosine analog, NECA (1 μM) or a selective adenosine
A2A receptor agonist (CGS 21680, 1 μM) for 2 hours (for real-time PCR) or 4 hours (for Western blot and ELISA). Where indicated, astrocytes were
pre-treated for 30 minutes with selective adenosine A2A receptor antagonist (ZM 241385, 250 nM) or adenosine A2B receptor antagonist (MRS
1754, 250 nM), prior to NECA stimulation. (A and B) show real-time PCR analyses of LIF gene expression (relative to GAPDH) in wild-type and A2B
knock-out astrocytes, respectively. Data are normalized to the control and presented as Mean± SEM of three independent experiments. P< 0.05.
(C) shows Western blot analyses to detect LIF protein levels in wild-type astrocytes. β-actin served as a loading control. (D) shows a
representation of sandwich ELISA experiment performed to detect LIF content in supernatants of cultured wild-type astrocytes. Each bar
corresponds to the mean concentration of LIF in triplicate samples; error bars indicate SEM. Observations were confirmed by repeating the
experiments two additional times. P< 0.05. NECA, 5′-N-ethylcarboxamide.
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http://www.jneuroinflammation.com/content/9/1/198stimulates cyclic AMP (cAMP) leading to PKA activa-
tion or Exchange Protein Activated by cAMP (EPAC)
signaling pathways [46], whereas Gq/11 proteins stimu-
late PKC via phospholipase C (PLC). In order to deter-
mine which pathway downstream of the A2B receptor is
responsible for NECA-induced LIF expression and re-
lease, we used specific inhibitors of PKA and PKC (KT
5720 and Ro 31–8220, respectively) [47]. Pre-incubation
of astrocytes with KT 5720 (250 nM, added 30 minutes
before NECA) did not affect NECA-induced LIF expres-
sion (both mRNA and proteins) (Figure 5A and 5B).
However, pre-treatment with Ro 31-8220 (250 nM,
added 30 minutes before NECA) reduced NECA-
induced LIF mRNA (Figure 5A) as well as protein levels
(Figure 5B). Consistently, Ro 31-8220, but not KT 5720,
suppressed LIF content in the supernatant from NECA-
treated astrocyte cultures (Figure 5C), indicating that
adenosine A2B receptor-mediated LIF expression and
release from astrocytes require PKC, but not PKA,
activation.
Basal and NECA-induced LIF expression and secretion
levels in primary astrocytes are dependent on ERK1/2-
and p38- but not on JNK-MAPK activation
Activation of the PKC pathway has been associated
with effects mediated through mitogen-activated protein
kinase (MAPK) signaling [48,49]. In order to determine
the involvement of MAPKs in NECA-induced LIF ex-
pression and release, specific inhibitors of the three
MAPK cascades: p38, extracellular signal-regulated kin-
ase (ERK) 1/2, and c-Jun N-terminal kinase (JNK) (SB
203580, U 0126 and SP 600125, respectively), were
used. It is shown here that pre-treatment (2 hours be-
fore NECA) of cultured astrocytes with SB 203580
(10 μM) and U 0126 (5 μM) significantly reduced basal
as well as NECA-induced LIF mRNA expression
(Figure 6A) and protein release (Figure 6B). On the
other hand, pre-treatment with SP 600125 (10 μM,
added 2 hours before NECA) affected neither basal, nor
NECA-induced LIF mRNA expression or protein re-
lease (Figure 6A and 6B), suggesting that both p38 and
ERK1/2, but not JNK, are important for basal, as wellas NECA-induced, LIF expression and release in cul-
tured astrocytes.
Basal and NECA-induced LIF expression and secretion
levels in primary astrocytes are dependent on NF-κB
activation
IL-6 gene expression in cultured astrocytes is enhanced
by NECA [36,38], similar to our present findings with
LIF. Since NF-κB is a key transcription factor that regu-
lates IL-6 gene expression [50,51], we wondered whether
NECA-induced LIF gene expression is similarly regu-
lated by NF-κB. Analysis of the mouse LIF promoter re-
gion (using Genomatix-MatInspector software (http://
www.genomatix.de/)), identified multiple consensus bind-
ing sequences for NF-κB at the first 500 bp upstream to
the transcription start site (data not shown). Treatment
of cultured astrocytes with NECA (1 μM) for 0.5, 1, 2
and 4 hours, induced activation of NF-κB, which was
detected by phosphorylation of NF-κB p65 subunit by
Western blot (Figure 7A). In addition, the specific in-
hibitor of NF-κB activation, BAY 11-7082 (10 μM;
added 2 hours before NECA) reduced NECA-induced
phosphorylation of NF-κB p65 (Figure 7A) and signifi-
cantly inhibited basal as well as NECA-induced LIF ex-
pression (both mRNA and protein) and release
(Figure 7B–D), strongly indicating that LIF gene expres-
sion is regulated by NF-κB.
LIF secretion in primary astrocytes is constitutive and
independent of NECA stimulation
Supernatants from untreated astrocytes contained basal
levels of LIF, suggesting that it could be constitutively
released from these cells. Since we observed increased
LIF concentrations in astrocyte supernatants after NECA
stimulation, we investigated whether or not NECA
played a direct role in LIF secretion. Thus, we blocked
the early secretory pathway with Brefeldin A (BFA), a
fungal metabolite that causes Golgi-derived proteins
to accumulate in the endoplasmic reticulum [52]. Cul-
tured astrocytes were pre-treated for 1 hour with BFA
(5 μg/mL), followed by treatment without or with NECA
(1 μM) for 1 or 4 hours (for immunocytochemistry and
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Figure 4 Effect of signaling pathway inhibitors on survival of cultured astrocytes. Primary cortical astrocytes were treated without or with
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http://www.jneuroinflammation.com/content/9/1/198LIF-ELISA, respectively). In BFA-treated cells, all LIF-
immunoreactivity co-localized with the Golgi marker
Giantin (Figure 8B), compared to control conditions,
where punctate LIF stainings could be observed all over
the cytoplasm (Figure 8A). LIF levels in the supernatants
from BFA-treated (5 μg/mL, for 5 hours) astrocyte cul-
tures were significantly lower than that of the control
(Figure 8C), implying that LIF is indeed constitutively
secreted. Moreover, NECA treatment (1 μM, for 4 hours)
did not stimulate LIF secretion in BFA-treated astrocytes
(Figure 8C), further indicating that increased LIF levels
in astrocytic culture supernatants after NECA stimula-
tion require synthesis of new proteins and does not in-
volve a ready-releasable post-Golgi reservoir of LIF.
LIF secretion in primary astrocytes is mediated through
recycling endosomes
We further investigated the type of organelles respon-
sible for LIF release. Several reports have shown that
cytokines such as IL-6 and transforming growth factor β
(TGFβ) are secreted through specialized secretory gran-
ules called large dense-core vesicles (LDCV) [53,54].
However, when astrocytes were co-stained for LDCV
markers such as Chromogranin A&B, or pHogrin and
LIF, no co-localization was observed (Figure 9A and 9B).
In contrast, co-localization between LIF and clathrin
was observed (Figure 9C). Clathrin is a marker for
endosomal vesicles and is sometimes used as a markerfor constitutive release [55,56]. Furthermore, LIF par-
tially co-localized with Rab11 (Figure 9D), which is a
marker for recycling endosomes [57,58], suggesting
that recycling endosomes, rather than LDCV, mediate
secretion of LIF.
NECA-treated astrocytes induce LIF-mediated protection
of cultured cortical neurons against excitotoxicity
We have previously shown that recombinant mouse LIF
(rmLIF) protein protects mouse cortical neurons against
excitotoxicity [13]. In order to understand whether
NECA stimulation of astrocytes specifically would in-
duce accumulation of neuroprotective LIF, astrocyte cul-
tures were refreshed with new media shortly before
NECA stimulation (1 μM for 4 hours) and the super-
natant was collected. As shown in Figure 10, pre-
treatment (1:1 dilution, for 24 hours) with supernatant
from NECA-treated astrocytes significantly reduced
the glutamate-induced cell death of cultured cortical
neurons. A similar protective effect was observed by
pre-treatment with rmLIF (0.1 ng/mL, for 24 hours)
(Figure 10). Pre-treatment of the neurons (for 24 hours
before application of glutamate) with NECA (1 μM) or
supernatant from untreated astrocytes did not affect
glutamate-induced neuronal cell death (Figure 10). We
further investigated whether neuroprotection induced by
NECA-treated astrocyte supernatant was mediated by
LIF, by incubating the supernatants for 1.5 hours at 37°C
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for 2 hours (for real-time PCR) or 4 hours (for Western blot and ELISA). Where indicated, astrocytes were pre-treated for 30 minutes with specific
inhibitors of PKA (KT 5720, 250 nM) or PKC (Ro 31–8220, 250 nM), prior to NECA stimulation. (A) shows real-time PCR analysis of LIF gene
expression (relative to GAPDH). Data are normalized to the control and presented as Mean± SEM of three independent experiments. P< 0.05. (B)
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http://www.jneuroinflammation.com/content/9/1/198with a LIF-neutralizing antibody (goat polyclonal anti-
LIF, AF449, 100 ng/mL, R&D Systems, Oxford, UK) be-
fore applying to the neuronal cultures. The optimum
concentration of LIF-neutralizing antibody was standar-
dized by an efficiency test, performed according to man-
ufacturer’s recommendations (data not shown). In
addition, the effect of rmLIF protein treated with LIF-
neutralizing antibody, on neuronal survival against glu-
tamate, served as a control (Figure 10). Interestingly,
LIF-neutralized supernatant from NECA-treated astrocytecultures failed to protect neurons against glutamate
(Figure 10), suggesting a direct neuroprotective mechanism
of the endogenous LIF produced by astrocytes in response
to NECA stimulation.
Discussion
We have previously shown that recombinant LIF pro-
tects neurons against glutamate-induced excitotoxicity
[13]. In this study, we investigated the mechanism by
which astrocytes produce and release LIF. Here we show
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Figure 6 Basal and NECA-induced leukemia inhibitory factor (LIF) expression and secretion levels in primary astrocytes are dependent
on ERK1/2- and p38- but not on JNK-MAPK activation. Primary cortical astrocytes were treated without or with NECA (1 μM) for 2 hours (for
real-time PCR) or 4 hours (for ELISA). Where indicated, astrocytes were pre-treated for 2 hours with specific inhibitors of ERK1/2 (U 0126, 5 μM),
p38 (SB 203580, 10 μM) or JNK (SP 600125, 10 μM) pathways, prior to NECA stimulation. (A) shows real-time PCR analysis of LIF gene expression
(relative to GAPDH). Data are normalized to the control and presented as Mean± SEM of three independent experiments. P< 0.05. (B) shows a
representation of sandwich ELISA experiment performed to detect LIF content in supernatants of cultured astrocytes. Each bar corresponds to the
mean concentration of LIF in triplicate samples; error bars indicate SEM. Observations were confirmed by repeating the experiments two
additional times. P< 0.05. ERK, extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; NECA,
5′-N-ethylcarboxamide.
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http://www.jneuroinflammation.com/content/9/1/198that glutamate-induced neuronal excitotoxicity leads to
adenosine receptor-mediated increase in LIF mRNA ex-
pression in cultured cortical astrocytes. We demonstrate
that the upregulation of LIF mRNA and protein is ad-
enosine A2B receptor-dependent, and is mediated
through Gq/11-PLC-PKC-MAPK-NF-κB signaling path-
ways. We furthermore show that LIF is transiting
through the Golgi and is found in recycling endosomes
rather than in LDCV. Finally, LIF produced by astro-
cytes can protect neurons against excitotoxicity.
It has been known for more than a decade that astro-
cytes are the major source for LIF in the CNS
[18,19,59,60]. However, the factors responsible for the
regulation of LIF expression in these cells are still largely
unknown. It is well known that stressed neurons release
nucleotides such as ATP and adenosine [30,61]. Re-
cently, it was demonstrated that astrocytes increase LIF
production and release in response to ATP receptor
stimulation [18]. In this study, the authors demonstrate
that neurons during action potentials can secrete ATP,which triggers LIF production in astrocytes. This ATP-
dependent upregulation of LIF by astrocytes is respon-
sible for the promotion of oligodendrocyte-mediated
myelination around neuronal axons. ATP is also known
to be secreted by neurons during stressful conditions
such as seizure, ischemia and hypoxia [26,27]. However,
when we blocked adenosine receptors with the non-
selective antagonist caffeine, or with specific A2A/A2B re-
ceptor antagonists, the effect of glutamate-stressed neur-
onal supernatants on LIF expression in astrocytes was
absent, suggesting that adenosine, but not ATP, is re-
sponsible for astrocytic LIF production during
glutamate-induced neuronal stress. Thus, it might be
hypothesized that depending on the CNS status, astro-
cytic LIF expression and secretion is differentially regu-
lated; during normal neuronal activity and development
ATP is involved whereas during neuronal insults, adeno-
sine might enhance LIF secretion by astrocytes.
Several studies have demonstrated the involvement of
adenosine A2B receptors in the regulation of IL-6
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http://www.jneuroinflammation.com/content/9/1/198expression in various cell types in vitro [38,47,48,62,63]
as well as in vivo [64], suggesting that A2B receptors
might also be essential in the regulation of other IL-6-
type cytokines. Our results show that adenosine-
dependent LIF regulation is mediated through the A2B
receptor, since no increase in LIF expression was found
in cultured astrocytes from A2B receptor deficient mice.
Instead NECA caused a down-regulation of LIF mRNA
after 8 and 24 hours in these cells, indicating that knock-
ing out A2B receptors may have unmasked an inhibitory
effect on LIF mRNA expression of an unidentified ad-
enosine receptor. Whether or not this might explain the
very short-lived effect of NECA on LIF mRNA expres-
sion in wild-type astrocytes is at the moment unclear
and a subject of future investigations. We furthermore
demonstrated that A2B-mediated LIF expression is
dependent on the PKC, but not the PKA pathway. Thesedata are in line with the study of Aloisi and colleagues,
which demonstrated that LIF modulation by pro-
inflammatory cytokines in human astrocytes was
mediated through PKC activation [59]. Moreover, PKC
has also been shown to be essential in IL-6 regulation
[47,48,62,65], revealing a prominent role for PKC in the
signaling pathway controlling LIF gene expression.
MAPKs have been reported to be involved in adeno-
sine A2B receptor-mediated regulation of IL-6 gene ex-
pression in astrocytoma cells [48]. In our experiments,
both basal as well as NECA-induced LIF gene expression
and release in cultured astrocytes were inhibited by spe-
cific inhibitors of p38 and ERK1/2, but not JNK-MAPKs.
In line with our findings, it has been shown that LIF ex-
pression in Schwann cells is mediated through PKC
pathway-induced ERK1/2 activation [49]. Furthermore,
we show here that adenosine-dependent LIF expression
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http://www.jneuroinflammation.com/content/9/1/198in astrocytes is regulated through the NF-κB transcrip-
tion factor. This observation is in line with several stud-
ies showing an NF-κB-dependent regulation of IL-6 gene
by this transcription factor in several cell types
[38,50,51,65,66]. It has been shown that NECA-induced
NF-κB activation and the resultant IL-6 gene expression
was abolished by inhibitors of MAPK pathways [65]. In
our study, preliminary observations indicate that NECA-
induced activation of the NF-κB pathway is reduced by
selective inhibitors of p38 and ERK1/2 pathways (data
not shown), suggesting that these pathways might play
as upstream mediators in NF-κB-dependent LIF expres-
sion in astrocytes.
Recent evidence indicates that, depending on the cell
type, different secretory pathways are employed for cyto-
kine release [67]. For example, T cells use two different
release mechanisms: IL-2 and IFN-γ are secreted at the
immunological synapse whereas CCL3 and TNF-α are
secreted multidirectionally, suggesting different secretory
pathways [68]. In neurons or neuron-like cells, secretory
granules called LDCVs are the organelles used for
the selective secretion of IL-6, TGF-β2 and CCL21
[53,54,69]. The same organelles are also used in immune
cells such as mast cells and neutrophils [67]. Here weshow that LIF protein is transported through Golgi but
its secretion by astrocytes is not mediated by secretory
granules. Instead, LIF co-localizes with Rab11, a known
marker of recycling endosomes [57,58]. Moreover, we
observed a partial co-localization of LIF with clathrin,
which also associates with recycling endosomes where it
is implicated in protein sorting [56]. Recycling endo-
somes have now been shown to be responsible for cyto-
kine secretion in several cell types. For example, IFN-γ
and TNF-α secretion from natural killer cells require
Rab11 [70]. Recycling endosomes are also responsible
for the constitutive secretion of IL-6 and TNF-α in
macrophages [71]. Further studies will be needed to bet-
ter understand LIF sorting, trafficking and release by
these vesicles.
Interestingly, our data indicate that LIF is constitu-
tively released from astrocytes. Indeed constant levels of
LIF were present in the supernatants of untreated astro-
cytes when measured by ELISA. Similar data were
observed in human astrocyte cultures [59]. Whether this
observation is representative of the physiological behav-
ior of astrocytes in vivo or is due to the culture condi-
tions remains to be determined. We further show that
by blocking the early secretory pathway with BFA, the
LIF pHogrin
A
LIF Chromogranin A&B
B
LIF Clathrin
C
LIF Rab11
D
Merge
Merge
Merge
Merge
Figure 9 Leukemia inhibitory factor (LIF) co-localizes with clathrin and Rab11 but not with large dense-core vesicle markers.
Immunostaining performed in cultured astrocytes revealed that LIF does not co-localize with pHogrin (A) and Chromogranin A & B (B), which are
both markers for large dense-core vesicles. However, we observed a massive co-localization of LIF with clathrin (C) and a partial co-localization
with Rab11 (D). Scale bars correspond to 10 μm.
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http://www.jneuroinflammation.com/content/9/1/198LIF concentration in the culture supernatant was not
increased upon NECA stimulation. The inhibitory effect
of BFA indicates that LIF passes through the Golgi
prior to its secretion, and thus does not follow non-
conventional secretory pathways that by-pass the Golgi
and is typically insensitive to BFA, which has recently
been reported to be used by other cytokines [72]. Im-
portantly, the inhibitory effect of BFA suggests that
NECA-stimulated release of LIF by astrocytes requiresde novo LIF synthesis, and does not involve a ready-
releasable post-Golgi pool of LIF.
It is now clear that one of the major roles of LIF is
directed toward cell protection. Indeed, it has been
shown that LIF is up regulated in astrocytes and neurons
after cerebral ischemia [21] as well as in astrocytes after
cortical brain injury [24], suggesting a role of LIF in
neuronal repair or protection. In line with these data,
treatment of rat with LIF prevented loss of motoneurons
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Figure 10 Effect of untreated and NECA-treated astrocyte supernatants on survival of cultured cortical neurons against excitotoxicity.
Primary cortical neurons were treated without or with recombinant mouse Leukemia inhibitory factor (rmLIF, 0.1 ng/mL), NECA (1 μM) or
astrocyte supernatants (untreated or treated with 1 μM NECA for 4 hours; diluted 1:1 in neuronal culture medium) for 24 hours. Where indicated,
rmLIF and NECA-treated astrocyte supernatants were treated with an anti-LIF neutralizing antibody (AF449; 100 ng/mL for 1.5 hours) before
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assessed 24 hours after glutamate treatment by a colorimetric MTT assay. The optical densities were measured at 570 nm, with a 630 nm and
blank correction. Data are normalized to percent of control and presented as Mean± S.E.M of four independent experiments. P< 0.05, when
compared to glutamate-treated condition. NECA, 5′-N-ethylcarboxamide.
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http://www.jneuroinflammation.com/content/9/1/198after peripheral nerve injury [73,74] and protection of
retinal ganglia cells was compromised in LIF knock-out
mice after lens injury [12]. Finally, LIF was shown to limit
demyelination in an experimental autoimmune enceph-
alomyelitis mouse model [16] and has become a promin-
ent therapeutic candidate for multiple sclerosis [17]. We
have previously shown that LIF can protect cortical as
well as hippocampal neurons against glutamate-induced
excitotoxicity [13]. Here we show that LIF coming from
the supernatant of NECA-treated astrocytes has the same
protective effect. Indeed, astrocytes produce several other
cytokines and neurotrophic factors including IL-6, NGF,
brain-derived neurotrophic factor, neurotrophin-3, S-
100β protein and TGFβ [75], that might help neurons to
cope with excitotoxic stress. Accordingly, conditioned
media from astrocyte cultures protected cortical neurons
against glutamate (data not shown). In order to confine
the neuroprotective effect of astrocytic factors that are
released in response to NECA treatment, we had to re-
fresh astrocyte culture medium prior to NECA treatment
and testing supernatant on glutamate-stressed neurons.
This, together with LIF neutralization, indicates that
LIF produced by astrocytes after adenosine receptor
stimulation is necessary to witness neuronal protec-
tion. Our results provide further evidence for a role
of adenosine in neuronal protection. Indeed, it has
been shown that adenosine can protect neurons dur-
ing hypoxia [76,77], ischemia [78,79] and excessive
neuronal activity [80,81]. This adenosine protection is
often mediated through the A1 receptor subtype [82-
84], but here we show that an indirect protection of
adenosine through the stimulation of A2B receptor on
astrocytes leading to LIF upregulation exists. This A2Breceptor activation might be related to an anti-
inflammatory process as observed previously by
others [85-87].
Conclusions
We demonstrate a protective role of LIF against glutam-
ate neurotoxicity and we provide clear evidence that ad-
enosine is required for an increased production of LIF
by astrocytes. These data further confirm a neuroprotec-
tive role of adenosine in the brain.
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